BullFrog AI Holdings has achieved a significant milestone in precision oncology research with the acceptance of its abstract for presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. The study, conducted in collaboration with Eleison Pharmaceuticals and researchers from Moffitt Cancer Center, demonstrates how artificial intelligence can identify patient subtypes with potential enhanced response to glufosfamide in pancreatic adenocarcinoma.
AI-Driven Patient Stratification Approach
The research, titled "Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma," explores data-driven precision-oncology approaches to identify specific patient populations that may demonstrate improved therapeutic outcomes. The study leverages BullFrog AI's proprietary bfLEAP® and bfPREP™ platforms to analyze complex clinical datasets and uncover biologically meaningful patient clusters.
Co-authored by Richard Kim, MD, Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center, and Nikolas Naleid, MD, PharmD, Hematology/Oncology Fellow at Moffitt Cancer Center, the research represents a collaborative effort between academic medicine and AI-driven drug development.
Clinical Significance for Pancreatic Cancer Treatment
Glufosfamide, an investigational chemotherapeutic agent being developed by Eleison Pharmaceuticals for pancreatic cancer, serves as the therapeutic focus of this precision medicine study. The research aims to identify which patients are most likely to benefit from this treatment approach, potentially improving clinical outcomes in one of oncology's most challenging malignancies.
"This acceptance by ASCO underscores the growing recognition of AI's ability to transform oncology research," said Vin Singh, CEO of BullFrog AI. "Our collaboration with Eleison Pharmaceuticals clearly demonstrates how causal AI can help reveal critical insights that guide more precise, effective treatment strategies for difficult cancers like pancreatic adenocarcinoma."
Presentation and Publication Details
The abstract will be featured in Poster Session B on January 9, 2026, during the ASCO Gastrointestinal Cancers Symposium scheduled for January 8-10, 2026, in San Francisco, California. Following the presentation, the research will be published in the ASCO GI 2026 online proceedings and subsequently appear in the Journal of Clinical Oncology (JCO) supplement corresponding to the symposium.
In accordance with ASCO's embargo policy, detailed study results will remain confidential until the official embargo lifts prior to the presentation, ensuring the integrity of the peer-review process and maintaining scientific standards for data disclosure.
Technology Platform Validation
The acceptance of this abstract provides further validation of BullFrog AI's technology platform in the precision oncology space. The company's bfLEAP® and bfPREP™ platforms are designed to analyze complex biological data using causal AI and machine learning approaches, with the goal of streamlining therapeutics development and reducing failure rates in clinical trials.
BullFrog AI positions itself as a technology-enabled drug development company that leverages artificial intelligence and machine learning to advance drug discovery and development through collaborations with leading research institutions. The company's approach focuses on using causal AI to analyze complex biological datasets and identify patterns that may not be apparent through traditional analytical methods.
